Skip to content
Search

Latest Stories

New Medicine Service expanded to cover 12 new conditions from September 1

The new medicine service (NMS) will be expanded to cover 12 new therapeutic conditions from September 1, the Pharmaceutical Services Negotiating Committee (PSNC) informed today (August 23), as it published the outcome of the negotiations on Year Three of the community pharmacy contractual framework.

From September 1, contractors can offer patients support to manage twelve additional conditions:


  • Acute coronary syndrome (ACS);
  • Atrial fibrillation (AF);
  • Coronary heart disease;
  • Epilepsy;
  • Glaucoma;
  • Gout;
  • Heart failure;
  • Hypercholesterolaemia ;
  • Osteoporosis;
  • Parkinson’s Disease;
  • Stroke / transient ischemic attack; and
  • Urinary incontinence and retention.

The conditions previously covered by the service will remain in place, PSNC said, adding that the NHS Business Services Authority (NHSBSA) will shortly publish an updated list of medicines that are suitable for NMS, covering the above conditions.

After the expansion to the service, an increase in the cap on the number of NMS which can be provided by contractors has also been agreed, the negotiator said.

“The cap will be increased from 0.5 per cent to one per cent of monthly prescription volume and additional bandings will also be included. The maximum remuneration for the service remains at £28 per NMS.”

Besides, the service will be amended to allow the opportunity for NMS to be offered to support carers of patients and the parents or guardians of children newly prescribed medication who could benefit from the service but where the patient is not able to provide informed consent themselves.

Catch-up NMS

As part of the NHS Covid-19 recovery plan, the temporary introduction of catch-up NMS has been agreed. This will enable patients, who were prescribed a new medicine during the pandemic, but could not receive NMS support at the time, to access a catch-up NMS.

Future development

Further therapeutic areas will be piloted through the Pharmacy Integration Fund to inform any future expansion of the service. This will support the further development of the service as part of a service model fully integrated with the wider Primary Care.

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less